Furthermore, genetic variants in the targets of insulin/insulin analogues, GLP-1 analogues, and thiazolidinediones were not associated with the risk of any stroke, any ischemic stroke and ICH (Fig. 2; Table 1). The gene discussed is INS; the disease is ischemic stroke.